De-escalation of Medical Therapies in HER2-positive Metastatic Breast Cancer in Long-term Persistent Response and Minimal Residual Disease Undetectable in Circulating Tumor DNA
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors UNICANCER
- 18 Oct 2024 New trial record